Who
Gylvin Lykke Hinsch
Director
Company insider
Files Form 4 as: Director, ProQR Therapeutics.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Jun 2026
- Last trade
- 2 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 30 Jun 2026 | PRQR ProQR Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,595 at $0.00 | filing |
| 2 Jun 2026filed 30 Jun 2026 | PRQR ProQR Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,595 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | PRQR ProQR Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,495 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | PRQR ProQR Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,495 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.